Manuel Muñoz‐Torres

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

H. A. P. Pols, Dieter Felsenberg, David A. Hanley et al. · Osteoporosis International · 1999 · 594 citations

Bone Disease, Bone Health, Low Bone Mass +8

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Alan J. Garber, Allen B. King, Stefano Del Prato et al. · The Lancet · 2012 · 323 citations

Diabetes Management, Insulin Degludec, Diabetes +7

Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus

Antonia García‐Martin, Pedro Rozas-Moreno, Rebeca Reyes‐García et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 310 citations

Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis

Francisco Gallego-Rojo, Jorge L. González-Calvin, Manuel Muñoz‐Torres et al. · Hepatology · 1998 · 243 citations · Full text

Relation Between Vitamin D Insufficiency, Bone Density, and Bone Metabolism in Healthy Postmenopausal Women

Pedro Mezquita‐Raya, Manuel Muñoz‐Torres, Juan de Dios Luna et al. · Journal of Bone and Mineral Research · 2001 · 213 citations · Full text